FDA approves Avance nerve graft for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities – Axogen
Axogen, Inc. announced that the FDA has approved the Biologics License Application (“BLA”) for Avance (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of… read more.
